Identification of FGF21mRNA, protein and the effect of recombinant FGF21 on cardiac function and infarct size.

FGF21 mRNA [Fig. 2A1] and protein expression [Fig. 2A2]; βKlotho mRNA [Fig. 2A3] and protein expression [Fig. 2A4] in isolated rat cardiomyocytes [A] and rat heart [B]. Fig. 1B:Immunocyto/histochemistry and confocal analysis of FGF21 protein in isolated adult rat cardiomyocytes [B1] and rat heart [B2]. MW.- Molecular Weight Marker for PCR products; BP.- Base Pairs; kDa.-kilo daltons. Fig. 2C-(a): Trace recordings of left ventricular developed pressure [LVDP (mmHg)] and left ventricular contractility (dp/dt) in control (saline treated) groups; and Fig. 2C-(b):[LVDP-mmHg] and dp/dt ratio in FGF21 treated groups - following 30 mins of global ischemia and 120 mins reperfusion. Fig. 2D: Rate pressure product [RPP (mmHg/min)] during global ischemia and reperfusion with or without FGF21 treatment [**PFig. 2E: Graphical representation of infarct area (%) in rat hearts treated with or without FGF21. Data shown are means ± SEM (n = 6, in triplicates). ***P